Monoclonal antibodies in cancer treatment: Where do we stand after 10 years?
- 31 December 1986
- journal article
- review article
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 5 (2) , 109-117
- https://doi.org/10.1016/s0167-8140(86)80165-7
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- IMAGING OF T-CELL LYMPHOMA BY RADIOLABELLED MONOCLONAL ANTIBODYThe Lancet, 1984
- Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody.Journal of Clinical Oncology, 1984
- Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis.Proceedings of the National Academy of Sciences, 1984
- A chlorambucil-anti-CEA conjugate cytotoxic for human colon adenocarcinoma cells in vitroBritish Journal of Cancer, 1984
- THERAPEUTIC USE OF HUMAN MONOCLONAL ANTIBODIESThe Lancet, 1983
- Selective cytotoxicity against human tumour cells by a vindesine-monoclonal antibody conjugateBritish Journal of Cancer, 1983
- Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth.Proceedings of the National Academy of Sciences, 1983
- Antitumor monoclonal antibodies for radioimmunodetection of tumors and drug targetingCancer and Metastasis Reviews, 1983
- Tomoscintigraphy for detecting gastrointestinal and medullary thyroid cancers: first clinical results using radiolabelled monoclonal antibodies against carcinoembryonic antigen.BMJ, 1982
- Immunotoxins: hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumour cellsNature, 1981